NeuBase Therapeutics, Inc. Deferred Offering Costs
NeuBase Therapeutics, Inc. had Deferred Offering Costs of $196.72 thousand as of 2020-03-31, per its 10-Q filed 2020-05-14.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2020-05-14
- 2020-03-31: Deferred Offering Costs $196.72K.
| Period end | Deferred Offering Costs |
|---|---|
| 2020-03-31 | $196.72K 10-Q · filed 2020-05-14 |